Auron Therapeutics is developing next-generation targeted cancer therapies by identifying and targeting the drivers of the disrupted cell states found in cancer, and reverting cancer cells from a plastic, proliferative cell state to a more mature, non-proliferative cell state. Using its AURIGIN™ platform, Auron is building a pipeline of small molecule targeted therapies, led by AUTX-703, for the treatment of both solid tumors and hematologic malignancies.
Auron Presents New Preclinical Data for AUTX-703 in Small Cell Lung Cancer (SCLC)
Newton, MA, April 3, 2025 – Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced data from a poster presentation at the 2025 Hot Topic in Basic and Translational Science: Small Cell Lung Cancer Meeting in New York, NY.